Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues.

Abstract:

:Gastrointestinal stromal tumor (GISTs) are the most common connective tissue malignancies of the gastrointestinal (GI) tract, with an incidence on the order of 10-13 per million people per year. Primary therapy is usually surgical, but the recurrence rate of large, so-called high-risk tumors, with a high mitotic rate, or those arising from small bowel and colon/rectum is particularly high. The natural history, pathology, and molecular biology of GISTs are discussed in this review, as are features of increasing our analytical power of the genes altered in these tumors, surgical issues, and the translation of research findings into clinical practice. The biological features of GIST make it a model for the examination of kinase-targeted therapeutics in solid tumors.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Reichardt P,Hogendoorn PC,Tamborini E,Loda M,Gronchi A,Poveda A,Schöffski P

doi

10.1053/j.seminoncol.2009.06.002

subject

Has Abstract

pub_date

2009-08-01 00:00:00

pages

290-301

issue

4

eissn

0093-7754

issn

1532-8708

pii

S0093-7754(09)00102-X

journal_volume

36

pub_type

杂志文章,评审
  • High-dose therapy for breast cancer.

    abstract::In recent years, the most frequent indication for high-dose autologous stem-cell-supported chemotherapy in the United States has been breast cancer. This approach is applied in "high-risk," early-stage disease as adjuvant treatment, and with either curative or palliative intent in metastatic disease. Among both lay pe...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hudis CA,Münster PN

    更新日期:1999-02-01 00:00:00

  • The alpha interferons: clinical overview.

    abstract::The clinical development of the recombinant alpha interferons has provided a prototype for the clinical development of biological compounds. With over 5,000 patients now treated with these compounds, some general principles have emerged that have wider implications for phase I-II strategies for testing other biologica...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,评审

    doi:

    authors: Spiegel RJ

    更新日期:1987-06-01 00:00:00

  • Beyond detectable minimal residual disease in chronic lymphocytic leukemia.

    abstract::Lymphoproliferative disorders are characterized by the abnormal accumulation of aberrant lymphocytes, which frequently interfere with the processes associated with immunologic response and hematopoiesis. Chronic lymphocytic leukemia (CLL) has traditionally been considered indolent, with a prolonged clinical course. Ho...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.01.026

    authors: Hillmen P

    更新日期:2006-04-01 00:00:00

  • Serotonin antagonists in the management of cisplatin-induced emesis.

    abstract::Cisplatin is recognized as an active chemotherapeutic agent in a broad variety of human tumors. The severe emetic effects of cisplatin, however, result in both acute and delayed emesis syndromes causing considerable morbidity. Over the last decade, the standard of therapy for control of cisplatin-induced emesis has be...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Perez EA,Hesketh PJ,Gandara DR

    更新日期:1991-02-01 00:00:00

  • Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer.

    abstract::The majority of patients with advanced prostatic cancer respond either to castration or estrogen therapy. In an attempt to identify an alternative hormonal therapy, 25 symptomatic stage D prostate cancer patients were treated with megestrol acetate as initial hormonal therapy. Thirty-three patients were evaluable for ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Bonomi P,Pessis D,Bunting N,Block M,Anderson K,Wolter J,Rossof A,Slayton R,Harris J

    更新日期:1985-03-01 00:00:00

  • New perspectives on the toxicity of etoposide.

    abstract::Etoposide has been used in the treatment of a wide variety of neoplasms, including small cell lung cancer. Kaposi's sarcoma, testicular cancer, acute leukemia, and lymphoma. Its current therapeutic use is limited by myelosuppression, particularly neutropenia. Pharmacodynamic studies of etoposide show that this toxicit...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Kobayashi K,Ratain MJ

    更新日期:1992-12-01 00:00:00

  • Moving disease biology from the laboratory to the clinic.

    abstract::To address the urgent need for novel therapies for multiple myeloma (MM), long-term research efforts have characterized the mechanisms whereby MM cells home to the bone marrow and adhere to bone marrow stromal cells and extracellular matrix proteins. Research also characterizes the functional sequelae of this binding ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.34072

    authors: Anderson KC

    更新日期:2002-12-01 00:00:00

  • Prognostic factors in renal carcinoma.

    abstract::Identification of tumor-, patient-, or treatment-related prognostic factors in renal carcinoma (RC) would allow the most appropriate application of current and future therapy to patients with this poorly responsive malignancy. Stage, including degree of lymph node and venous involvement, and grade remain the most powe...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Rini BI,Vogelzang NJ

    更新日期:2000-04-01 00:00:00

  • Unusual variants of melanoma: fact or fiction?

    abstract::Evidence is reviewed separating unusual variants of melanoma from the large group of superficial spreading and nodular (SSM/NOD) histogenetic types. These include (1) the relationship of moles to melanoma of the SSM/ NOD types not found in melanoma arising in lentigo maligna (LMM), desmoplastic neurotrophic melanoma (...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Sagebiel RW

    更新日期:1996-12-01 00:00:00

  • The Veterans Precision Oncology Data Commons: Transforming VA data into a national resource for research in precision oncology.

    abstract::The Department of Veterans Affairs (VA) has a strong track record providing high-quality, evidence-based care to cancer patients. In order to accelerate discoveries that will further improve care for Veterans with cancer, the VA has partnered with the Center for Translational Data Science at the University of Chicago ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2019.09.002

    authors: Do N,Grossman R,Feldman T,Fillmore N,Elbers D,Tuck D,Dhond R,Selva L,Meng F,Fitzsimons M,Ajjarapu S,Ayandeh S,Hall R,Do S,Brophy M

    更新日期:2019-01-01 00:00:00

  • Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.

    abstract::Although originally developed as an antitumor agent in the 1970s, dexrazoxane (DEX) is currently used as a cardioprotective agent in combination with doxorubicin (DOX). Due to concerns about anthracycline-induced cardiotoxicity at higher cumulative doses, many investigators have chosen to administer DOX by prolonged i...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Synold TW,Tetef ML,Doroshow JH

    更新日期:1998-08-01 00:00:00

  • The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma.

    abstract::Many patients with Hodgkin's and non-Hodgkin's lymphoma (NHL) can be cured today with combination chemotherapy and/or radiotherapy. However, for patients with suboptimal responses to initial therapy or for patients with refractory or relapsed disease, salvage therapy alone is usually inadequate to achieve long-term su...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Laport GF,Williams SF

    更新日期:1998-08-01 00:00:00

  • Antifolates in clinical development.

    abstract::Many novel antifolate compounds with unique pharmacologic properties are currently in clinical development. These newer antifolates differ from methotrexate, the most widely used and studied drug in this class, in terms of their lipid solubility and cellular transport affinity, their level of polyglutamation, and thei...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Takimoto CH

    更新日期:1997-10-01 00:00:00

  • Novel strategies for the early detection and prevention of lung cancer.

    abstract::Lung cancer is the leading cause of cancer death in the United States. Despite evidence of molecular abnormalities in biological specimens, progress in this disease is hampered by the lack of diagnostic markers useful for clinical practice. The majority of patients with lung cancer are still diagnosed at an advanced s...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.02.009

    authors: Wardwell NR,Massion PP

    更新日期:2005-06-01 00:00:00

  • A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.

    abstract::This randomized, multinational, multicenter study was designed to determine the response rate of gemcitabine monotherapy and cisplatin/etoposide combination therapy in chemotherapy-naive patients with advanced, recurrent, and/or metastatic non-small cell lung cancer (stage IIIA [if inoperable], IIIB, or IV). One group...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Manegold C,Drings P,von Pawel J,Ricci S,Dornoff W,van Walree N,ten Bokkel Huinink W,Chemaissani A,Stahel P,Bergman B,Wagenius G,Sederholm C,Mattson K,Liippo K,Kellokumpu-Lehtinen P

    更新日期:1997-06-01 00:00:00

  • Advances in imaging in the postoperative patient with a rising prostate-specific antigen level.

    abstract::Imaging prostate cancer continues to represent a clinical challenge for both primary and recurrent disease. In the evaluation of the persistent/recurrent/metastatic prostate cancer, knowledge of cancer location (local v distant), size, and extent are essential in order to design a treatment, tailored to each patient's...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00359-2

    authors: Hricak H,Schöder H,Pucar D,Lis E,Eberhardt SC,Onyebuchi CN,Scher HI

    更新日期:2003-10-01 00:00:00

  • Clinical experience with denileukin diftitox (ONTAK).

    abstract::Denileukin diftitox (ONTAK; Seragen Inc, San Diego, CA) is a fusion protein designed to direct the cytocidal action of diphtheria toxin to cells that overexpress the IL-2 receptor. The human IL-2 receptor exists in three isoforms: low (CD25), intermediate (CD122/CD132), and high (CD25/CD122/CD132) affinity. The high-a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.12.017

    authors: Foss F

    更新日期:2006-02-01 00:00:00

  • Monoclonal antibodies for the prevention and treatment of graft-versus-host disease.

    abstract::Acute and chronic graft-versus-host disease (GvHD) remain major obstacles to successful allogeneic hematopoietic stem cell transplantation, contributing substantially to morbidity and non-relapse mortality. Better understanding of the immunopathophysiology of GvHD has identified a number of targets for intervention. A...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00250-1

    authors: Bruner RJ,Farag SS

    更新日期:2003-08-01 00:00:00

  • Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.

    abstract::The current study was conducted to determine the risk of adverse outcomes among patients with monoclonal gammopathy of undetermined significance (MGUS) of the IgM class. Two hundred thirteen patients with IgM MGUS were identified in southeastern Minnesota from 1960 to 1994. The primary end point was progression to lym...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/sonc.2003.50062

    authors: Kyle RA,Therneau TM,Rajkumar SV,Offord JR,Larson DR,Plevak MF,Melton LJ 3rd

    更新日期:2003-04-01 00:00:00

  • Imaging of lung cancer: old and new.

    abstract::Lung cancer is the leading cause of cancer death in the United States. Lung cancer is frequently encountered by the radiologist, whether the lung cancer is detected on a chest radiograph obtained in a symptomatic patient, or is an incidental finding. The radiologic workup of pulmonary lesions suspected of being lung c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Broderick LS,Tarver RD,Conces DJ Jr

    更新日期:1997-08-01 00:00:00

  • Genetic changes associated with testicular cancer susceptibility.

    abstract::Testicular germ cell tumor (TGCT) is a highly heritable cancer primarily affecting young white men. Genome-wide association studies (GWAS) have been particularly effective in identifying multiple common variants with strong contribution to TGCT risk. These loci identified through association studies have implicated mu...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.08.004

    authors: Pyle LC,Nathanson KL

    更新日期:2016-10-01 00:00:00

  • Total necrosis of hepatocellular carcinoma with a combination therapy of arterial infusion of chemotherapeutic lipiodol and transcatheter arterial embolization: report of 14 cases.

    abstract::Combination therapy consisting of Lipiodol (Laboratoire Guerbet, Villepinte, France) containing styrene maleic acid neocarzinostatin and transcatheter arterial embolization (L-TAE) has been an important conservative therapy for hepatocellular carcinoma (HCC). We examined the clinical and pathologic characteristics of ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Kenji J,Hyodo I,Tanimizu M,Tanada M,Nishikawa Y,Hosokawa Y,Mandai K,Moriwaki S

    更新日期:1997-04-01 00:00:00

  • Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.

    abstract::The availability of subcutaneously (SC) administered amifostine may present an advantage for radioprotectant therapy in head and neck cancer patients. In a randomized phase II trial comparing SC amifostine versus no amifostine in 140 patients undergoing radiation therapy for head and neck, thoracic, or pelvic cancers,...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1053/sonc.2002.37350b

    authors: Anné PR

    更新日期:2002-12-01 00:00:00

  • Adjuvant therapy in rectal cancer: a protocol proposal.

    abstract::The use of adjuvant radiation therapy and chemotherapy diminishes the likelihood of local-regional and distant recurrences and appears to prolong survival in patients who have undergone a complete surgical resection of a Dukes-Kirklin stage B2 or C rectal cancer. Patients with this malignant condition rarely develop p...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Mayer RJ

    更新日期:1985-09-01 00:00:00

  • The new staging system for cutaneous melanoma in the era of lymphatic mapping.

    abstract::In 2002, the American Joint Committee on Cancer (AJCC) revised the staging system for cutaneous melanoma on the basis of a survival analysis of important melanoma prognostic factors. Features of the revised system include new strata for primary tumor thickness, incorporation of primary tumor ulceration as an important...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.03.018

    authors: Rousseau DL Jr,Gershenwald JE

    更新日期:2004-06-01 00:00:00

  • Combined modality treatment for prostate cancer: role of chemotherapy.

    abstract::Chemotherapy for prostate cancer currently has an established role in the treatment of hormone-refractory prostate cancer. There is strong evidence that combined modality treatment with androgen ablation in addition to radiotherapy provides a benefit above and beyond radiotherapy alone in patients with a poor prognosi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00274-4

    authors: Sandler HM,Narayan S,Smith DC

    更新日期:2003-08-01 00:00:00

  • Vinorelbine (Navelbine) in the treatment of breast cancer: a summary.

    abstract::One of the new agents intensively studied in the last decade for the treatment of metastatic breast cancer is vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France). This vinca alkaloid produces response rates comparable to other single agents in women with m...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Abeloff MD

    更新日期:1995-04-01 00:00:00

  • Is there a place for "dose-dense" weekly schedules of the taxoids?

    abstract::The recommended weekly dose and the maximum tolerated weekly dose of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) have yet to be determined. We report that a weekly dose of up to 40 mg/m2 docetaxel for 6 weeks is active in pretreated patients with metastatic breast cancer. From a preliminary study, this d...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Löffler TM

    更新日期:1998-10-01 00:00:00

  • CPT-11: clinical experience in phase I studies.

    abstract::Phase I studies of CPT-11 (irinotecan) have been conducted in Europe, the United States, and Japan to determine the maximum tolerated dose (MTD) and the most appropriate intravenous administration schedule for further evaluation in phase II investigations. Diarrhea and/or neutropenia were the major dose-limiting toxic...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Armand JP

    更新日期:1996-02-01 00:00:00

  • The use of ondansetron in patients receiving multiple-day cisplatin regimens.

    abstract::The control of nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy has remained difficult, even with the use of combination antiemetic regimens containing metoclopramide. Although these patients receive a lower daily dose of cisplatin, the emetogenic potential remains high. In addition, many ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hainsworth JD

    更新日期:1992-08-01 00:00:00